• Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP)
  • Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms
  • ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life